Harnessing hepatitis B core-related antigen measurement to optimize posttreatment monitoring.
作者信息
Tsai Ying-Nan, Wu Jia-Ling, Hsu Yao-Chun
机构信息
Division of Gastroenterology and Hepatology, E-Da Cancer Hospital, I-Shou University, Kaohsiung, Taiwan.
School of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan.
出版信息
Clin Mol Hepatol. 2024 Apr;30(2):293-296. doi: 10.3350/cmh.2024.0101. Epub 2024 Feb 19.
Abstract
摘要
相似文献
1
Harnessing hepatitis B core-related antigen measurement to optimize posttreatment monitoring.
Clin Mol Hepatol. 2024 Apr;30(2):293-296. doi: 10.3350/cmh.2024.0101. Epub 2024 Feb 19.
2
Hepatitis B core-related antigen: Are we near a treatment endpoint?
World J Gastroenterol. 2022 Jul 21;28(27):3532-3534. doi: 10.3748/wjg.v28.i27.3532.
3
Quantitative Hepatitis B Surface Antigen, the Trustworthy Biomarker for Functional Cure of Chronic Hepatitis B.
Gut Liver. 2023 Mar 15;17(2):179-180. doi: 10.5009/gnl230070.
4
Letter regarding "Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation".
Clin Mol Hepatol. 2024 Apr;30(2):269-271. doi: 10.3350/cmh.2024.0064. Epub 2024 Jan 31.
5
Antiviral therapy, HBsAg seroclearance and late recurrence of hepatitis B-related hepatocellular carcinoma.
J Hepatol. 2022 Nov;77(5):1471-1472. doi: 10.1016/j.jhep.2022.07.005. Epub 2022 Jul 19.
6
Reply: Benefits of stopping therapy in patients with cirrhotic hepatitis B, true effect, or residual confounding?
Hepatology. 2024 Mar 1;79(3):E97-E98. doi: 10.1097/HEP.0000000000000641. Epub 2023 Oct 20.
7
Letter to the Editor: Benefits of stopping therapy in patients with cirrhotic hepatitis B, true effect or residual confounding?
Hepatology. 2024 Mar 1;79(3):E95-E96. doi: 10.1097/HEP.0000000000000639. Epub 2023 Oct 20.
8
Severity of Hepatitis B Relapse After Cessation of Nucleos(t)ide Analog: Need a Closer Look!
Clin Gastroenterol Hepatol. 2022 Aug;20(8):1885-1886. doi: 10.1016/j.cgh.2021.09.004. Epub 2021 Sep 9.
9
[Research progress of biomarkers of hepatitis B virus and clinical significance].
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2023 Dec 25;40(6):1242-1248. doi: 10.7507/1001-5515.202309041.
10
Hepatic histologic and immunohistochemical changes in chronic hepatitis B after prolonged clearance of hepatitis B e antigen and hepatitis B surface antigen.
Ann Intern Med. 1991 Jul 15;115(2):113-5. doi: 10.7326/0003-4819-115-2-113.
本文引用的文献
1
Letter regarding "Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation".
Clin Mol Hepatol. 2024 Apr;30(2):269-271. doi: 10.3350/cmh.2024.0064. Epub 2024 Jan 31.
2
Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation.
Clin Mol Hepatol. 2024 Jan;30(1):98-108. doi: 10.3350/cmh.2023.0194. Epub 2023 Dec 14.
3
Letter: Estimating the incidence of HBsAg seroclearance after cessation of tenofovir and entecavir - potential influence of censored observation.
Aliment Pharmacol Ther. 2024 Jan;59(1):136-137. doi: 10.1111/apt.17767.
4
Hepatitis B core-related antigen: A novel and promising surrogate biomarker to guide anti-hepatitis B virus therapy.
Clin Mol Hepatol. 2023 Oct;29(4):851-868. doi: 10.3350/cmh.2022.0434. Epub 2023 Mar 9.
5
The Role of Off-Therapy Viral Kinetics in the Timing and Severity of Flares in Hepatitis B e Antigen-Negative Patients.
Clin Gastroenterol Hepatol. 2023 Jun;21(6):1533-1541.e11. doi: 10.1016/j.cgh.2022.08.021. Epub 2022 Aug 28.
6
APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients.
Hepatol Int. 2021 Aug;15(4):833-851. doi: 10.1007/s12072-021-10223-5. Epub 2021 Jul 23.
7
Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk.
Aliment Pharmacol Ther. 2019 Jan;49(1):107-115. doi: 10.1111/apt.15058. Epub 2018 Nov 19.
8
Distinct Relapse Rates and Risk Predictors After Discontinuing Tenofovir and Entecavir Therapy.
J Infect Dis. 2018 Mar 28;217(8):1193-1201. doi: 10.1093/infdis/jix690.
9
Variable selection - A review and recommendations for the practicing statistician.
Biom J. 2018 May;60(3):431-449. doi: 10.1002/bimj.201700067. Epub 2018 Jan 2.
10
Methods for time-varying exposure related problems in pharmacoepidemiology: An overview.
Pharmacoepidemiol Drug Saf. 2018 Feb;27(2):148-160. doi: 10.1002/pds.4372. Epub 2017 Dec 28.
Zotero 插件